Recent developments in the treatment of migraine in children and adolescents
Abstract
Only in recent years has there been a mandate, if you would, to study newer pharmaceutical agents in children and adolescents. As such, there is a paucity of well controlled clinical trials, let alone drugs that have been through registration trials in these age groups. Migraine, while less common especially in children than adults however still requires treatment. This has led healthcare providers to utilize treatments from the ?adult? world in these younger patients. Even in the adult population there are relatively few agents that are approved by the Food and Drug Administration (FDA) or other regulatory bodies compared to the many treatments that are given for the treatment of migraine. These treatments have varying levels of evidence for efficacy and tolerability. Multiple guidelines and recommendations have been published in recent years examining the evidence based medicine of migraine treatment offering guidance oriented towards primary care clinicians and neurologists whose primary focus is not headache medicine.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.